<DOC>
	<DOCNO>NCT01382030</DOCNO>
	<brief_summary>Neo- adjuvant chemotherapy use high-risk soft tissue sarcoma improve systemic control . Patients trial treat 4 cycle chemotherapy ( EIA , etoposide , ifosfamide , adriamycin ) preoperatively , follow local surgery radiotherapy . An additional 4 cycle adjuvant chemotherapy administer . Treatment response assess MRI CT scan FDG-PET subgroup patient .</brief_summary>
	<brief_title>Neoadjuvant Adjuvant Chemotherapy High-risk Soft Tissue Sarcoma</brief_title>
	<detailed_description>The role chemotherapy high-risk soft tissue sarcoma controversial . Though many patient undergo initial curative resection , distant metastasis frequent event result 5-year overall survival rate 50 - 60 % . Neo-adjuvant adjuvant chemotherapy apply achieve pre-operative cytoreduction , assess chemosensitivity eliminate occult metastasis . The current protocol comprises cycle neoadjuvant chemotherapy ( ( EIA , etoposide 125 mg/m2 iv day 1 4 , ifosfamide 1500 mg/m2 iv day 1 - 4 , doxorubicin 50 mg/m2 day 1 , pegfilgrastim 6 mg sc day 5 ) , local surgery radiotherapy well 4 cycle adjuvant EIA . Treatment response assess MRI CT scan FDG-PET subgroup patient .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Soft tissue sarcoma histology Tumor size &gt; = 5 cm Deep/extracompartimental localization Grade 2/3 ( FNCLCC ) Patients inadequate previous therapy Age 1865 year normal bone marrow function normal liver function normal renal function Karnofsky index &gt; =80 % Chordoma Chondrosarcoma Kaposi´ sarcoma Neuroblastoma Mesothelioma Osteosarcoma/Ewings´sarcoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>High-risk</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>